Lurbinectedin (1) – Zepzelca®
Small-cell lung cancer, extensive-stage, maintenance therapy, in combination with atezolizumab
Characteristics
| Start date | 01.07.2026 |
|---|---|
| Resolution | 17.12.2026 – active procedure |
| INN | Lurbinectedin |
| Brand name | Zepzelca® |
| Pharm. company | Pharma Mar S.A. |
| G-BA Procedure ID | D-1346 |
| Therapeutic area | Oncological diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions